Stereotactic radiosurgery (SRS) has become a cornerstone in the multidisciplinary management of complex intracranial vascular lesions and skull-base tumors. Over the last decade, international multicenter studies \u2014 many of which include contributions from Dr. Mohana Rao Patibandla \u2014 have refined our understanding of SRS for arteriovenous malformations (AVMs) and skull-base meningiomas, clarifying indications, outcomes, volumetric response patterns, and safety considerations. At Dr. Rao\u2019s Hospital in Guntur, these evidence signals inform patient selection, technical planning, and follow-up pathways, enabling local patients to access world-class, data-driven radiosurgical care close to home.<\/p>\n
\n
This article summarizes the current evidence base, highlights key publications with Dr. Patibandla as a co-author, and explains how this body of work is operationalized at Dr. Rao\u2019s Hospital for the benefit of patients and referral partners.<\/p>\n
SRS delivers a conformal, high-dose radiation target to a lesion in one or a few sessions with submillimeter accuracy. For selected AVMs and skull-base meningiomas, SRS offers:<\/p>\n
\n
A non-invasive option when open surgery carries prohibitive morbidity, or when lesions are surgically inaccessible (e.g., deep brain AVMs, central skull base meningiomas).<\/p>\n<\/li>\n
High local control rates for small- to medium-sized meningiomas while preserving adjacent cranial nerve function when careful dose planning and volumetric constraints are observed.<\/p>\n<\/li>\n
A treatment pathway that can be combined with staged microsurgery, fractionated radiotherapy, or observation depending on patient and lesion factors.<\/p>\n<\/li>\n
Evidence from international multicenter consortia has clarified which lesion subgroups benefit most from SRS, how radiation dose and target volume predict outcomes, and what long-term surveillance strategies are effective. These multicenter analyses allow repeated findings to be validated across institutions, equipment types, and patient populations \u2014 strengthening clinical confidence in SRS protocols.<\/p>\n
The following selected publications \u2014 many authored or coauthored by Dr. Patibandla \u2014 are among the most influential studies shaping current practice. Links to the publications are provided so clinicians can review methodology and results in full.<\/p>\n
\n
SRS for Spetzler-Martin Grade III AVMs.<\/strong> An international multicenter study evaluated outcomes of SRS for Grade III AVMs and provided important data on obliteration rates and hemorrhage risk over time; this work is frequently cited when counseling patients about radiosurgical outcomes for intermediate-grade AVMs.<\/p>\n \n SRS for Spetzler-Martin Grade IV & V AVMs.<\/strong> Multicenter analysis of higher-grade AVMs (IV & V) provided pragmatic outcome data that help stratify which high-risk lesions might still be appropriate for radiosurgical strategies (for example, staged SRS or combined modality approaches) versus when conservative management may be preferable.<\/p>\n \n Posterior Fossa (WHO Grade I) Meningiomas \u2014 Volumetric Outcomes.<\/strong> Long-term volumetric evaluations of posterior fossa meningiomas treated with SRS indicate reasonably high local control with structured follow-up and underscore the importance of dose planning in preventing cranial nerve toxicity.<\/p>\n \n Central Skull Base Meningiomas \u2014 Volumetric Evaluation & Long-Term Outcomes.<\/strong> Central skull base meningiomas present particular challenges because of intimate cranial nerve and brainstem relationships; volumetric SRS series in the literature have demonstrated meaningful tumor control with acceptable cranial neuropathy rates when careful planning is performed.<\/p>\n \n Foramen Magnum and Posterior Fossa Meningiomas \u2014 Multicenter Experience.<\/strong> Additional multicenter studies provide outcome benchmarks specifically for foramen magnum lesions and posterior fossa meningiomas, informing margin selection and surveillance intervals.<\/p>\n \n Endocrine-Related Radiosurgery (Pituitary Targets).<\/strong> Dr. Patibandla has also contributed to international SRS literature on functional pituitary targets (Cushing\u2019s disease, acromegaly), which illustrates multidisciplinary radiosurgery practice principles, dose constraints, and endocrine follow-up pathways that are informative for skull base work.<\/p>\n \n Collectively, these multicenter works move beyond single-center series: they provide reproducible metrics such as volumetric tumor reduction, obliteration curves for AVMs, cranial nerve preservation rates, and timeframes for expected radiographic responses. These are essential parameters for shared decision-making with patients.<\/p>\n \n <\/p>\n At Dr. Rao\u2019s Hospital, evidence from the multicenter literature underpins a systematic, multidisciplinary workflow for radiosurgical candidates. Key components include:<\/p>\n \n Every potential SRS candidate \u2014 whether for AVM or skull base meningioma \u2014 is reviewed in a multidisciplinary forum involving neurosurgery, neuro-radiology, radiation oncology, neuro-anesthesia, and neurorehabilitation. This forum evaluates surgical risk, radiosurgical candidacy, and whether staged or multimodality therapy is preferable.<\/p>\n \n AVMs:<\/strong> SRS is considered for small to medium AVMs (<10\u201312 mL typically), deep and eloquent location AVMs where surgical morbidity is high, and certain higher-grade AVMs after careful multidisciplinary assessment (taking cues from published Spetzler-Martin multicenter outcomes). For very large AVMs, staged SRS or multimodality treatment may be proposed.<\/p>\n<\/li>\n Skull base meningiomas:<\/strong> SRS is often recommended for small-to-medium sized tumors, residual\/recurrent tumors following surgery, or for surgically inaccessible central skull base and posterior fossa meningiomas where cranial nerve preservation is paramount. Volumetric data help guide fractionation and dose.<\/p>\n<\/li>\n High-resolution MRI with thin slices, contrast sequences, and fused CT angiography (for AVMs) provide the accurate structural and vascular maps required for contouring. For AVMs, digital subtraction angiography (DSA) remains the gold standard in many cases and is integrated into planning when needed. Institutional imaging protocols align with those used in major multicenter studies to allow comparable dosimetric decisions and outcome tracking.<\/p>\n \n Radiation dose and fractionation are chosen based on lesion size, proximity to critical structures (brainstem, cranial nerves), and published volumetric outcome data. For example, smaller skull base meningiomas may be treated with a single-fraction high-dose SRS regimen if critical distances permit; where nerves or brainstem proximity is close, hypofractionated SRS (fractionated stereotactic radiotherapy) may be selected to decrease cranial neuropathy risk \u2014 an approach supported by multicenter experience.<\/p>\n \n Patients receive structured counselling about expected radiographic response timelines (e.g., months to years for volumetric reduction), possibilities of transient radiation-induced swelling, and the small but real risk of delayed cranial neuropathy or radionecrosis. Prognostic metrics derived from multicenter series (obliteration curves for AVMs, actuarial local control for meningiomas) are used to provide evidence-based probabilities.<\/p>\n \n Standardized follow-up protocols include MRI at 6 months, 12 months, then annually for 3\u20135 years (adjusted by pathology and response). For AVMs, DSA is used selectively to confirm obliteration, particularly if MRI suggests complete response. All outcomes are logged in a structured database to permit continuous quality assessment and contribute to local and international research activities.<\/p>\n The international multicenter AVM studies led by collaborators including Dr. Patibandla provide real-world outcome rates used in clinical counseling. For instance, Grade III AVMs treated with SRS demonstrate meaningful obliteration rates over a multi-year timeline with variable hemorrhage risk during the latency period after radiosurgery \u2014 data that shape follow-up intensity and urgent care planning.<\/p>\n \n Large multicenter work on Grade IV\u2013V AVMs demonstrates that while outcomes are more guarded, tailored strategies (staged SRS, combined embolization + SRS, or conservative management) can be considered within a framework of multidisciplinary risk assessment. These studies emphasize individualized care rather than one-size-fits-all algorithms.<\/p>\n \n For skull base meningiomas, volumetric analyses from World Neurosurgery and Journal of Neurosurgery cohorts show consistent long-term tumor control with low cranial nerve toxicity when volumetric limits and dose constraints are respected. These datasets are particularly useful in cases where resection would carry substantial morbidity.<\/p>\n \n Finally, the inclusion of pituitary radiosurgery studies (e.g., on Cushing\u2019s disease and acromegaly), while distinct in therapeutic goals, contributes to a common knowledge base about skull base radiosurgical planning, endocrine follow-up, and multidisciplinary coordination. These works illustrate how radiosurgery teams coordinate with endocrinology, neurosurgery, and radiation oncology for best outcomes.<\/p>\n \n SRS is not risk-free; responsible practice demands balancing benefit and harm. Key safety themes include:<\/p>\n Latency hemorrhage risk in AVMs:<\/strong> Patients treated with SRS face a latency period before obliteration; during this time, hemorrhage remains possible. Counselling and emergency plans are part of routine care. Multicenter data provide the best estimates of this risk by lesion grade and radiosurgical dose.<\/p>\n<\/li>\n Cranial nerve toxicity in skull base SRS:<\/strong> Careful dose fractionation and strict dose constraints to nerves and brainstem minimize cranial neuropathies; multicenter volumetric evaluations provide thresholds that guide safe planning.<\/p>\n<\/li>\n Radionecrosis and edema:<\/strong> Close imaging surveillance and low thresholds for corticosteroid management or surgical decompression (rare) ensure patient safety where symptomatic radiation effects occur.<\/p>\n<\/li>\n At Dr. Rao\u2019s Hospital, these risks are managed through evidence-informed protocols, real-time multidisciplinary decision making, and structured emergency pathways \u2014 the very elements proven in large multicenter cohorts.<\/p>\n The global multicenter collaborations that Dr. Patibandla has been part of reflect the modern scientific approach to complex neurosurgical problems: pooling cases across centers to achieve statistical power, harmonizing outcome definitions, and producing practice-informing data. Dr. Rao\u2019s Hospital maintains institutional data registries consistent with international reporting standards to enable local contributions to future multicenter efforts.<\/p>\n Priority areas for ongoing research include:<\/p>\n Prospective registries for AVM radiosurgery outcomes stratified by grade and prior embolization status.<\/p>\n<\/li>\n Volumetric imaging markers that predict early tumor response versus pseudoprogression in skull base meningiomas.<\/p>\n<\/li>\n Comparative studies of single-fraction versus hypofractionated SRS for central skull base lesions.<\/p>\n<\/li>\n Long-term cranial nerve function tracking after skull base radiosurgery.<\/p>\n<\/li>\n<\/ul>\n These initiatives will help continue the cycle of evidence generation and clinical refinement.<\/p>\n Stereotactic radiosurgery is a sophisticated, evidence-based tool in the neurosurgical armamentarium for AVMs and skull base meningiomas. Multicenter studies \u2014 to which Dr. Mohana Rao Patibandla has substantially contributed \u2014 provide the outcome benchmarks and safety thresholds that clinics like Dr. Rao\u2019s Hospital use to offer precision, documented, and patient-centered radiosurgical care. Patients and referring physicians seeking expert evaluation in Andhra Pradesh can rely on a multidisciplinary approach that emphasizes selection, safety, and long-term follow-up \u2014 the pillars of modern radiosurgical practice.<\/p>\n Ding D, Mehta GU, Patibandla MR<\/strong>, et al. Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study.<\/em> Neurosurgery. 2019;84(3):717\u2013725. doi:10.1093\/neuros\/nyy178.<\/a><\/p>\n<\/li>\n Patibandla MR,<\/strong> Ding D, Kano H, et al. Stereotactic radiosurgery for Spetzler-Martin Grade IV and V arteriovenous malformations: an international multicenter study.<\/em> J Neurosurg. 2018;129(2):498\u2013507. doi:10.3171\/2017.3.JNS162635.<\/a><\/p>\n<\/li>\n Patibandla MR<\/strong>, Lee C, Tata A, Addagada GC, Sheehan JP. Stereotactic radiosurgery for WHO grade I posterior fossa meningiomas: long-term outcomes with volumetric evaluation.<\/em> J Neurosurg. 2018;129(5):1249\u20131259. doi:10.3171\/2017.6.JNS17993.<\/a><\/p>\n<\/li>\n Patibandla MR<\/strong>, Lee C, Sheehan JP. Stereotactic radiosurgery of central skull base meningiomas \u2014 volumetric evaluation and long-term outcomes.<\/em> World Neurosurgery. 2017;108:176\u2013184. doi:10.1016\/j.wneu.2017.08.166.<\/a><\/p>\n<\/li>\n Mehta GU, Zenonos G, Patibandla MR<\/strong>, et al. Outcomes of stereotactic radiosurgery for foramen magnum meningiomas: an international multicenter study.<\/em> J Neurosurg. 2018;129(2):383\u2013389.<\/a><\/p>\n<\/li>\n Mehta GU, Gautam U., Patibandla MR<\/strong>, et al. Stereotactic Radiosurgery for Cushing\u2019s Disease: Results of an International, Multicenter Study.<\/em> J Neurol Surg B Skull Base. 2018.<\/a><\/p>\n<\/li>\n<\/ul>\n Dr. Rao\u2019s Hospital, Guntur \u2014 offers multidisciplinary radiosurgical evaluation and treatment planning for AVMs and skull base meningiomas. For consultation or referral:<\/p>\n Dr. Rao\u2019s Hospital<\/strong> \n Stereotactic radiosurgery (SRS) is a non-invasive treatment that delivers highly focused radiation to an arteriovenous malformation (AVM) in the brain. The radiation causes the abnormal blood vessels to gradually close over months to years, reducing the risk of future bleeding without open surgery.<\/p>\n Effectiveness depends on the size and grade of the AVM. Small to medium AVMs often show high obliteration rates over 2\u20133 years. Larger or higher-grade AVMs may require staged treatment or combined approaches. Regular follow-up imaging is essential to monitor response.<\/p>\n Yes, when carefully planned, stereotactic radiosurgery is considered a safe and effective option for small to medium skull base meningiomas. It is especially useful when tumors are close to cranial nerves or the brainstem, where open surgery may carry higher risk.<\/p>\n Most skull base meningiomas do not shrink immediately. Tumor growth usually stabilizes first, and gradual reduction may occur over months to years. Regular MRI scans are performed to monitor volumetric response.<\/p>\n Stereotactic radiosurgery is typically performed as a day-care procedure. Most patients go home the same day and can resume normal activities within a short period, depending on individual condition.<\/p>\n During the latency period before complete AVM closure, there remains a small risk of bleeding. Some patients may experience temporary swelling or radiation-related changes on MRI. Careful follow-up helps manage these risks.<\/p>\n Radiosurgery is often preferred when the lesion is deep, located in eloquent brain areas, near critical nerves, or when surgical risks are high. Each case is evaluated individually by a neurosurgical team.<\/p>\n Dr. Rao\u2019s Hospital in Guntur provides structured evaluation and treatment planning for AVMs and skull base meningiomas using evidence-based stereotactic radiosurgery protocols and multidisciplinary assessment.<\/p>\n Eligibility depends on lesion size, location, symptoms, previous treatments, and overall health. A detailed MRI and clinical evaluation by a neurosurgeon are required to determine suitability.<\/p>\n Yes. Long-term follow-up with MRI and, in selected AVM cases, angiography is necessary to confirm lesion response and ensure safe outcomes.<\/p>\n \n Official Website:<\/strong> https:\/\/drraoshospitals.com\/neww\/<\/a><\/p>\n<\/li>\n Neurosurgery Department:<\/strong> https:\/\/drraoshospitals.com\/neww\/neurosurgery\/<\/a><\/p>\n<\/li>\n Spine Surgery:<\/strong> https:\/\/drraoshospitals.com\/neww\/spine-surgery\/<\/a><\/p>\n<\/li>\n Neurology Services:<\/strong> https:\/\/drraoshospitals.com\/neww\/neurology\/<\/a><\/p>\n<\/li>\n About Dr. Mohana Rao Patibandla:<\/strong> https:\/\/drraoshospitals.com\/neww\/about-dr-mohana-rao\/<\/a><\/p>\n<\/li>\n Contact & Appointments:<\/strong> https:\/\/drraoshospitals.com\/neww\/contact\/<\/a><\/p>\n<\/li>\n<\/ul>\n YouTube<\/a><\/p>\n Facebook<\/a>\u00a0\u00a0<\/u><\/p>\n Instagram<\/a>\u00a0<\/u><\/p>\n Google GMB<\/a>\u00a0<\/u><\/p>\n<\/h2>\n
Translating Evidence to Practice: Patient Selection & Workflows at Dr. Rao\u2019s Hospital<\/h2>\n
1. Multidisciplinary Case Review<\/h3>\n
2. Indications & Contraindications<\/h3>\n
\n
3. Imaging & Targeting Protocols<\/h3>\n
4. Dose, Volume, and Fractionation Decisions<\/h3>\n
5. Patient Counselling & Shared Decision Making<\/h3>\n
6. Follow-up & Outcome Monitoring<\/h3>\n
<\/h2>\n
Practical Examples from the Literature<\/h2>\n
<\/h2>\n
Outcomes, Safety, and Risk Management<\/h2>\n
\n
<\/h2>\n
Research, Collaboration, and the Way Forward<\/h2>\n
\n
<\/h2>\n
Conclusion: Evidence Informs Care<\/h2>\n
<\/h2>\n
Selected References & Links (Representative publications with Dr. Patibandla contributions)<\/h2>\n
\n
<\/h2>\n
For Referrals and Patient Evaluation<\/h2>\n
12-19-67, Old Bank Road, Kothapet, Guntur, Andhra Pradesh
Phone: 090100 56444
Email: info@drraoshospitals.com<\/a>
Website: https:\/\/drraoshospitals.com\/neww\/<\/a><\/p>\nFrequently Asked Questions (FAQ)<\/h1>\n
What is stereotactic radiosurgery for AVM?<\/h2>\n
\nHow effective is stereotactic radiosurgery for AVMs?<\/h2>\n
\nIs stereotactic radiosurgery safe for skull base meningiomas?<\/h2>\n
\nHow long does it take for a meningioma to shrink after radiosurgery?<\/h2>\n
\nDoes radiosurgery require hospitalization?<\/h2>\n
\nWhat are the risks of radiosurgery for AVMs?<\/h2>\n
\nWhen is radiosurgery preferred over open brain surgery?<\/h2>\n
\nIs stereotactic radiosurgery available in Guntur?<\/h2>\n
\nHow do I know if I am a candidate for radiosurgery?<\/h2>\n
\nIs follow-up necessary after stereotactic radiosurgery?<\/h2>\n
\n